Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting (AGM) for Friday, September 11, 2026, at 3:30 pm. The meeting will be conducted through Video Conference or Other Audio-Visual Means (VC/OAVM), with the deemed venue fixed at the company’s registered office in Ahmedabad. This follows a board meeting held on August 17, 2026, where directors approved the convening of the AGM and proposed amendments to constitutional documents.

Financial Results for FY26

The primary ordinary business item involves the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. During FY26, the company reported a significant turnaround in profitability. Standalone revenue from operations rose to ₹11,234.04 lakh, up from ₹297.74 lakh in the previous year. The company posted a net profit of ₹37.50 lakh after tax, compared to a net loss of ₹69.51 lakh in FY25. Consolidated revenue stood at ₹11,602.21 lakh, with consolidated profit after tax at ₹39.44 lakh.

The Board did not recommend any dividend for the year under review. Reserves and surplus stood at ₹39.54 lakh as of March 31, 2026, compared to ₹2.04 lakh at the beginning of the year.

Board Appointments and Reappointments

Shareholders will consider the reappointment of Mr. Jayendra A. Mehta as Managing Director, who retires by rotation at this AGM and is eligible for reappointment. Additionally, the meeting will approve the regularization of Mr. H.A. Parikh as a Non-Executive Non-Independent Director. Mr. Parikh was initially appointed as an Additional Director with effect from June 18, 2026, and holds office until this AGM.

Other board changes disclosed include the appointment of Mr. Sarang B. Pathak as a Non-Executive Non-Independent Director effective August 30, 2025, and Mr. Hitesh Rijwani as an Independent Director effective May 12, 2025. Ms. Rina Kumari continues as an Independent Director.

Special Resolutions and Corporate Governance

The AGM will seek shareholder approval for several special resolutions:

• Related Party Transactions: Approval for material related party transactions during FY27, with an aggregate limit of up to ₹100 crore.
• Borrowing Limits: Increase in borrowing limits under Section 180(1)(c) of the Companies Act, 2013, allowing the board to borrow sums exceeding the aggregate of paid-up share capital, free reserves, and securities premium, up to ₹100 crore.
• Investments and Guarantees: Approval under Section 186 for investments, loans, guarantees, or securities up to ₹50 crore.
• Loans to Interested Entities: Approval under Section 185 for loans or financial assistance to entities in which directors are interested, up to ₹50 crore.
• Constitutional Documents: Adoption of new Memorandum of Association (MoA) and Articles of Association (AoA) aligned with the Companies Act, 2013.

E-Voting and Meeting Logistics

The cut-off date for determining member eligibility to attend and vote is September 4, 2026. Remote e-voting will be available from September 8, 2026, at 9:00 am to September 10, 2026, at 5:00 pm, through the National Securities Depository Limited (NSDL) e-voting system. Mr. Chintan K. Patel, a practicing company secretary, has been appointed as the scrutinizer to oversee the e-voting process. Participation in the VC/OAVM meeting is limited to 1,000 members on a first-come, first-served basis, excluding large shareholders holding 2% or more, promoters, institutional investors, and key managerial personnel.

Vivanza Biosciences Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange. The filing, dated August 8, 2026, discloses that the company’s Board of Directors approved the financial statements on August 7, 2026, after they were reviewed by the Audit Committee. This submission ensures regulatory compliance and provides investors with updated performance metrics for the initial quarter of FY27.

The intimation was issued under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jayendra Amichand Mehta, Managing Director of Vivanza Biosciences, signed the communication to the Corporate Relationship Department at BSE Limited. The company also published extracts of the financial results along with the limited review report in The Indian Express (English) and Financial Express (Gujarati), adhering to disclosure norms for regional accessibility.

Financial Review Details

The filing confirms that the full format of the financial results is available on the stock exchange websites and the company’s official portal. While the specific numerical values for revenue, profit, or other key performance indicators are not detailed in this intimation letter, the document serves as a formal notification of the availability of these figures for stakeholder review.

Shareholder Information

Alongside the financial results, Vivanza Biosciences highlighted a special window for the transfer and dematerialization of physical securities. In accordance with SEBI Circular No. HO/38/13/11(2) 2026-MIRSD-POD/1/3750/2026, the special window has been extended from February 5, 2026, to February 4, 2027. This facility allows shareholders to re-lodge transfer requests for physical shares that were previously rejected or returned due to deficiencies in documents or processes prior to April 1, 2019.

Eligible shareholders must ensure their ledger has a demat account and provide a Client Master List (CML) along with transfer documents and share certificates. All transfers processed during this period will be issued only in dematerialized form. Shareholders are advised to contact the Registrar to the Issue and Share Transfer Agent (RTA), Purva Shareregistry (I) Ltd, for further assistance.